166 related articles for article (PubMed ID: 18729799)
1. Catalyzing stem cell research.
Willemse L; Lyall D; Rudnicki M
Regen Med; 2008 Sep; 3(5):761-4. PubMed ID: 18729799
[TBL] [Abstract][Full Text] [Related]
2. Patents, commercialization and the Canadian stem cell research community.
Caulfield T; Ogbogu U; Murdoch C; Einsiedel E
Regen Med; 2008 Jul; 3(4):483-96. PubMed ID: 18588471
[TBL] [Abstract][Full Text] [Related]
3. The commercialization of human stem cells: ethical and policy issues.
Resnik DB
Health Care Anal; 2002; 10(2):127-54. PubMed ID: 12216741
[TBL] [Abstract][Full Text] [Related]
4. From human genes to stem cells: new challenges for patent law?
Caulfield TA
Trends Biotechnol; 2003 Mar; 21(3):101-3. PubMed ID: 12628363
[TBL] [Abstract][Full Text] [Related]
5. The attack of the clones: patent law and stem cell research.
Rimmer M
J Law Med; 2003 May; 10(4):488-505. PubMed ID: 12852321
[TBL] [Abstract][Full Text] [Related]
6. Biomedical patents and ethics: a Canadian solution.
Gold ER
McGill Law J; 2000 May; 45(2):413-35. PubMed ID: 12688288
[TBL] [Abstract][Full Text] [Related]
7. Biomedical research and the commercialization agenda: a review of main considerations for neuroscience.
Caulfield T; Ogbogu U
Account Res; 2008; 15(4):303-20. PubMed ID: 18972268
[TBL] [Abstract][Full Text] [Related]
8. [Ethical, legal and social issues on regenerative medicine].
Tsukata Y
Nihon Geka Gakkai Zasshi; 2004 Aug; 105(8):435-9. PubMed ID: 15373219
[TBL] [Abstract][Full Text] [Related]
9. Exploring innovation in stem cell and regenerative medicine in Japan: the power of the consortium-based approach.
Munisi HI; Xie Z; Sengoku S
Regen Med; 2014; 9(4):467-77. PubMed ID: 25159064
[TBL] [Abstract][Full Text] [Related]
10. Property, progeny, and patents.
Knowles LP
Hastings Cent Rep; 1999; 29(2):38-40. PubMed ID: 10321342
[No Abstract] [Full Text] [Related]
11. Commercial development of cell-based therapeutics: strategic considerations along the drug to tissue spectrum.
Parenteau NL
Regen Med; 2009 Jul; 4(4):601-11. PubMed ID: 19580408
[TBL] [Abstract][Full Text] [Related]
12. An exploratory survey on the views of European tissue engineers concerning the ethical issues of tissue engineering research.
Trommelmans L; Selling J; Dierickx K
Tissue Eng Part B Rev; 2009 Sep; 15(3):241-7. PubMed ID: 19290775
[TBL] [Abstract][Full Text] [Related]
13. Stem cell therapies and regenerative medicine in China.
Huang S; Fu X
Sci China Life Sci; 2014 Feb; 57(2):157-61. PubMed ID: 24430560
[TBL] [Abstract][Full Text] [Related]
14. Why regenerative stem cell medicine progresses slower than expected.
Rosemann A
J Cell Biochem; 2014 Dec; 115(12):2073-6. PubMed ID: 25079695
[No Abstract] [Full Text] [Related]
15. Patent prosecution strategies for stem cell related applications.
Kumar R; Yeh JJ; Fernandez D; Hansen N
J Biomol Screen; 2007 Sep; 12(6):769-74. PubMed ID: 17848639
[TBL] [Abstract][Full Text] [Related]
16. Policy and ethical issues in applying medical biotechnology in developing countries.
Bhardwaj M; Macer DR
Med Sci Monit; 2003 Feb; 9(2):RA49-54. PubMed ID: 12601306
[TBL] [Abstract][Full Text] [Related]
17. The hard cell.
Lewis R
Nature; 2007 Jun; 447(7145):748-9. PubMed ID: 17557381
[TBL] [Abstract][Full Text] [Related]
18. CellCAN: a unique enabler of regenerative medicine and cell therapy in Canada.
Roy DC; Alarco AM; Isasi R
Stem Cells Dev; 2014 Dec; 23 Suppl 1():24-8. PubMed ID: 25457957
[TBL] [Abstract][Full Text] [Related]
19. Patents: patenting of stem cell related inventions in Europe.
Rutz B; Yeats S
Biotechnol J; 2006 Apr; 1(4):384-7. PubMed ID: 16892264
[No Abstract] [Full Text] [Related]
20. [Ethical, legal and social issues in regenerative medicine].
Ida R
Nihon Rinsho; 2008 May; 66(5):991-6. PubMed ID: 18464522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
